Objetivo The department of Oncology of Crucell Holland BV, lead by Renate Zwijsen (PhD) is actively involved in the development and the commercialisation of monoclonal human antibodies, applying its MAbstract target discovery and antibody development technology and its PER.C6 human cell line technology for high-yielding antibody production.The department of Oncology intends on initiating a breast cancer research program aimed specifically at identifying antigens that are uniquely expressed in breast cancer and, thereafter, at developing human antibodies that selectively bind to these identified antigens. For this project, Crucell Holland BV has an exclusive arrangement with the University Medical Centre of Utrecht (UMC Utrecht) through which Crucell Holland BV will have a constant supply of fresh breast cancer tissue samples to be used for this research project. Ámbito científico medical and health sciencesclinical medicineoncologybreast cancer Programa(s) FP5-HUMAN POTENTIAL - Programme for research, technological development and demonstration on "Improving the human research potential and the socio-economic knowledge base" (1998-2002) Tema(s) Data not available Convocatoria de propuestas IHP-MCHI-01-1 Consulte otros proyectos de esta convocatoria Régimen de financiación Data not available Coordinador CRUCELL HOLLAND B.V. Aportación de la UE Sin datos Dirección Archimedesweg 4 LEIDEN Países Bajos Ver en el mapa Coste total Sin datos
